Randomisation | Group A | 7 (23.3) |
Group B | 9 (30.0) |
Group C | 1 (3.3) |
Group D | 13 (43.3) |
Demography | Age (years) | 54 ± 11 |
Height (m) | 1.65 ± 0.07 |
BMI (kg/m2) | 26.0 ± 4.6 |
Diagnosis | Adjuvant | 26 (86.7) |
Metastatic or local advanced | 4 (13.3) |
Tumour entity | Breast Cancer | 22 (73,33) |
Endometrial Cancer | 2 (6,7) |
Ovarian Cancer | 2 (6.7) |
Cervical Cancer | 4 (13,3) |
T-categories | T1 | 10 (33.3) |
T2 | 14 (46.7) |
T3 | 3 (10.0) |
T4 | 3 (10.0) |
Nodal status | N0 | 20 (66.7) |
N1 | 8 (26.7) |
N2 | 1 (3.3) |
N3 | 1 (3.3) |
Metastasis | M0 | 27 (90.0) |
M1 | 3 (10.0) |
Chemotherapy regimens | Paclitaxel/Carboplatin | 7 (23.3) |
Epirubicin/Cyclophosphamid | 22 (73.3) |
Docetaxel/Cyclophosphamid | 1 (3.3) |
Treatment | Adjuvant chemotherapy | 6 (20) |
Neoadjuvant chemotherapy | 22 (73.3) |
Palliative chemotherapy | 3 (10.0) |
Nutritional status (NRS 2002) | 1 | 21 (70.0) |
2 | 8 (26.7) |
3 | 1 (3.3) |
Energy requirement | Basal metabolic rate (kcal) | 1391 ± 125 |
Physical Activity Level | 1.39 ± 0.06 |
Active metabolic rate (kcal) | 1933 ± 178 |
25% of the active metabolic rate (kcal) | 484 ± 44 |